Qinan Yin

department of radiation oncology

H指数:18

被引数:1,005

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adaptive-to-maladaptive IRE1α signaling as a driver of amyloidogenic APP processing in Alzheimer’s disease

适应性至适应性不良的IRE1α信号作为阿尔茨海默病中淀粉样前体蛋白淀粉样变加工的驱动因素

Frontiers in Molecular Biosciences

IF4

2026-08-110

Unraveling role of arginine-NO metabolism by targeting HIF-1α signaling in mediating esophageal squamous cell carcinoma

靶向HIF-1α信号通路在揭示精氨酸-NO代谢在介导食管鳞状细胞癌中的作用

Frontiers in Molecular Biosciences

IF4

2026-07-150

PGAM1 Orchestrates Cell Cycle Progression, Glycolytic Reprogramming, and Immunosuppressive Microenvironment in Triple-Negative Breast Cancer

PGAM1调控三阴性乳腺癌中的细胞周期进程、糖酵解重编程和免疫抑制性微环境

IUBMB Life

IF3.2

2026-05-270

PRE

Mast cell driven immunometabolism as a therapeutic entry point in ESCC

肥大细胞驱动的免疫代谢作为食管鳞状细胞癌的 therapeutic entry point

Frontiers in Cell and Developmental Biology

IF4.3

2026-05-110

OAAI

Editorial: Exploring miRNA roles in cancer pathogenesis and treatment; volume III

编者按：探索miRNA在癌症发生和发展中的作用及治疗；卷III

Frontiers in Molecular Biosciences

IF4

2026-04-170

Development of a venous thromboembolism risk prediction model for patients with primary membranous nephropathy based on machine learning

基于机器学习的原发性膜性肾病患者的静脉血栓栓塞症风险预测模型开发

Frontiers in Pharmacology

IF4.8

2025-11-060

OAAI

A study on a real-world data-based VTE risk prediction model for lymphoma patients

基于真实世界数据的淋巴瘤患者VTE风险预测模型研究

Frontiers in Pharmacology

IF4.8

2025-10-140

OAAI

ABO Blood Group and the Risk and Prognosis of Diffuse Large B-Cell Lymphoma

ABO血型与弥漫性大B细胞淋巴瘤的风险和预后

Cancer Management and Research

IF2.6

2025-09-040

OAAI

Breaking immune evasion in breast cancer by targeting COX-2/PGE2 pathway

通过靶向COX-2/PGE2通路打破乳腺癌的免疫逃逸

Molecular and Cellular Endocrinology

IF3.6

2025-07-230

PRE

Mechanical forces and enzymatic digestion act together to induce the remodeling of collagen fibrils in tumor microenvironment

LAB ON A CHIP

IF5.4

2025-03-010

PRE

Development and validation of a prediction model for VTE risk in gastric and esophageal cancer patients

胃癌和食管癌患者静脉血栓栓塞风险预测模型的开发与验证

FRONTIERS IN PHARMACOLOGY

IF4.8

2025-02-280

CDKN3 as a key regulator of G2M phase in triple-negative breast cancer: Insights from multi-transcriptomic analysis

IUBMB LIFE

IF3.2

2025-01-260

PRE

Mechanical forces and enzymatic digestion act together to induce the remodeling of collagen fibrils in tumor microenvironment (vol 25,10.1039/D4LC00821A,2025)

机械力和酶消化共同作用以诱导肿瘤微环境中胶原原纤维的重塑（vol 25, 10.1039/D4LC00821A, 2025）

LAB ON A CHIP

IF5.4

2025-01-010

Inflammation and Immune Escape in Ovarian Cancer: Pathways and Therapeutic Opportunities

inflammation research

IF4.1

2025-01-011

Advanced machine learning unveils CD8+T cell genetic markers enhancing prognosis and immunotherapy efficacy in breast cancer

BMC CANCER

IF3.4

2024-10-010

OAAI

Replenishment of TCA cycle intermediates and long-noncoding RNAs regulation in breast cancer

乳腺癌中TCA循环中间体的补充和长链非编码rna的调控

MOLECULAR AND CELLULAR ENDOCRINOLOGY

IF3.6

2024-10-011

PRE

Efficacy and safety of a phase II study: Timdarpacept (IMM01) combined with azacitidine (AZA) as the first-line treatment in adults with chronic myelomonocytic leukemia (CMML)

II期研究的有效性与安全性：Timdarpacept (IMM01) 联合阿扎胞苷 (AZA) 作为慢性髓系单核细胞白血病 (CMML) 成年患者的一线治疗方案

ANNALS OF ONCOLOGY

IF65.4

2024-09-011

PRE

High Glycolytic Activity Signature Reveals CCNB2 as a Key Therapeutic Target in Triple-Negative Breast Cancer

FRONTIERS IN BIOSCIENCE-LANDMARK

IF3.1

2024-08-230

Unlocking the potential of pyroptosis in tumor immunotherapy: a new horizon in cancer treatment

释放焦亡在肿瘤免疫治疗中的潜力: 癌症治疗的新视野

FRONTIERS IN IMMUNOLOGY

IF5.9

2024-06-144

OAAI

Host Factors Modulate Virus-Induced IFN Production via Pattern Recognition Receptors

inflammation research

IF4.1

2024-06-011

Qinan Yin

个人简介

教育背景

工作经历

荣誉奖项

研究方向